Introducing PeptAI: Autonomous Agents for Peptide Drug Discovery
Introducing PeptAI on Tuesday, May 5th.
By Eda Arslan
Event details
Join us next Tuesday for a livestream unveiling PeptAI, a fleet of autonomous agents for peptide drug discovery.
More about PeptAI
Peptide drug discovery is bottlenecked by coordination cost between discovery, synthesis, and wet-lab validation. PeptAI removes those handoffs:
- Each agent runs a 9-gate pipeline 24/7 against a single receptor
- Every gate decision publishes openly on Molecule Labs
- Agents pay for their own wet-lab synthesis at Adaptyv Bio via x402
Two agents are running with candidates advancing, and a third has a lead ready for wet lab.
If successful, PeptAI validates a new model for autonomous biotech R&D: pre-IND-ready peptide assets produced end-to-end by agents, with every decision auditable on-chain.
The opportunity
- Peptide therapeutics: $49.5B market by 2030 (10.2% CAGR)
- 80+ FDA-approved peptide drugs, 150+ in active trials
- AI-driven drug discovery: $1.3B by 2030 (30%+ CAGR)
- PEPTAI holders co-own the proprietary wet-lab data generated across every candidate and receptor program, data biotech, pharma, and AI drug discovery companies actively buy
- Governance over target and receptor decisions, share in revenues from commercialized discoveries, early exposure to a pipeline heading to pre-IND
Roadmap
Live now:
- Agent-01 (GLP-1R): 35 candidates advancing
- Agent-02 (KISS1R): 2 of 10 advanced to G9
- Agent-03 (OX2R): lead candidate ready for wet lab
Next:
Q2 2026
- First on-chain wet-lab attestation via @Molecule_sci Labs
Q3 2026
- Autonomous iteration cycle proven, GLP-1R Gen 1 library, design-vs-nature bioRxiv preprint
Q4 2026
- Pipeline scales beyond GPCRs
Q1 2027
- Lead optimization at scale, pre-IND scoping
Q2 2027
- First in vivo studies, multi-target portfolio in parallel
Funding
- Initial Raise: $50K
- Starting FDV: $1M
- Initial Project Funding: $25K, with further unlocks tied to scientific milestones
RSVP now!